Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Eyconis to Participate in Upcoming Investor Conferences

By GlobeNewswire

REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announced that members of its management team will participate in one-on-one investor meetings at the following upcoming investor conferences:

Wells Fargo Virtual Private Biopharma Symposium
Date: November 4, 2026
Location: Virtual

Stifel 2026 Healthcare Conference
Date: November 10, 2026
Location: New York City

LifeSci Capital Conference
Date: November 16, 2026
Location: London

UBS Global Biopharma Conference
Date: November 17, 2026
Location: London

Piper Sandler 38th Annual Healthcare Conference
Date: December 1, 2026
Location: New York City

Investors interested in meeting with Eyconis should contact their representative at the applicable conference host.

About Eyconis

Eyconis, a clinical-stage biotechnology company, is advancing next-generation, long-acting ophthalmic therapeutics. Through an exclusive worldwide license in ophthalmology from Ascendis Pharma, Eyconis is utilizing the commercially validated TransCon® technology platform to develop therapies that have the potential to reduce treatment burden, optimize disease control, and improve visual outcomes in people with serious eye disease. Eyconis’ lead program, EYC-0305, is being developed as a long-acting anti-VEGF therapy for wet age-related macular degeneration, with potential applicability across other retinal diseases including diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. EYC-0305 is currently being evaluated in OVERTURE, a Phase 1b/2a clinical trial in treatment-naïve patients with wet age-related macular degeneration. Beyond EYC-0305, Eyconis is developing a broader pipeline of long-acting therapies across other ophthalmic indications with significant unmet need. For more information, visit www.eyconis.com.

Ascendis Pharma and TransCon are trademarks owned by the Ascendis Pharma group.

Contacts

Investor Contact
Chris Brinzey
ICR Healthcare
chris.brinzey@icrhealthcare.com

Media Contact
Ben Shannon
ICR Healthcare
ben.shannon@icrhealthcare.com


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.